Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. Company
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  11:31:24 2023-01-27 am EST
82.58 CHF   -0.12%
11:54aNovartis Says Initial Data from Phase 3 Trial Show No Difference Between Crizanlizumab, Placebo
MT
06:58aNovartis : provides update on Phase III STAND trial assessing crizanlizumab
PU
01/25Novartis Files Petition With Supreme Court to Protect Gilenya Patent
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- pharmaceutical products (81.3%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;

- generic drugs (18.7%; Sandoz).

Net sales break down geographically as follows: Switzerland (1.7%), Germany (9.4%), France (4.9%), Europe (23.1%), the United States (32.6%), the Americas (7%), China (5.9%), Japan (5.2%) and Asia-Africa-Australasia (10.2%).

Number of employees : 104 323 people.
Sales per Business
20202021Delta
Innovative Medicines36 618.1080.2%38 394.6081.3% +4.85%
Sandoz9 053.8719.8%8 805.3018.7% -2.75%
CHF in Million
Sales per region
20202021Delta
United States15 472.1033.9%15 376.1032.6% -0.62%
Europe10 282.5022.5%10 909.0023.1% +6.09%
Asia/Africa/Australasia4 544.7710%4 782.5310.1% +5.23%
Germany4 240.669.3%4 452.489.4% +4.99%
Canada and Latin America3 042.056.7%3 332.507.1% +9.55%
China2 415.055.3%2 790.345.9% +15.54%
Japan2 631.875.8%2 452.985.2% -6.8%
France2 292.105%2 305.784.9% +0.6%
Switzerland750.891.6%798.161.7% +6.29%
CHF in Million
Managers
Name Title Age Since
Vasant Narasimhan Chief Executive Officer 46 2018
Harry Werner Kirsch Chief Financial Officer 57 2013
Shreeram Aradhye Chief Medical Officer 59 2022
Steffen Lang President-Operations 55 2022
Klaus Moosmayer Chief Ethics, Risk & Compliance Officer 54 2018
Samir Shah, Dr. Global Head-Investor Relations - -
Charlotte Pamer-Wieser, Dr. Secretary - 2011
Elizabeth Theophille Chief Technology Transformation Officer 55 2020
Linda Kanitra Associate Director-Drug Development - -
Marie-France Tschudin Chief Commercial Officer - 2022
Members of the board
Name Title Age Since
J÷rg Reinhardt Non-Executive Chairman 66 2013
Andreas von Planta, Dr. Independent Non-Executive Director 67 2006
Charles L. Sawyers, Dr. Independent Non-Executive Director 63 2013
William Thomas Winters Independent Non-Executive Director 61 2013
Nancy C. Andrews, Dr. Independent Non-Executive Director 64 2015
Mary Elizabeth Doherty Independent Non-Executive Director 65 2016
Ton BŘchner Independent Non-Executive Director 57 2016
Frans Van Houten Independent Non-Executive Director 62 2017
Patrice Bula Lead Independent Director 66 2022
Bridgette P. Heller Director 61 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,403,721,252 2,092,926,588 87.1% 252,740,811 10.5% 87.1%
Shareholders
NameEquities%
Novartis AG 282,034,061 11.7%
Sandoz Family Foundation 89,135,960 3.71%
The Vanguard Group, Inc. 59,871,605 2.49%
UBS Asset Management Switzerland AG 55,730,682 2.32%
Norges Bank Investment Management 50,631,295 2.11%
Credit Suisse Asset Management (Schweiz) AG 50,012,984 2.08%
Wellington Management Co. LLP 48,697,381 2.03%
Novartis Foundation For Employee Participation 47,834,052 1.99%
Dodge & Cox 20,024,470 0.83%
Artisan Partners LP 18,087,944 0.75%
Holdings
NameEquities%Valuation
NOVARTIS AG (NOVN) 282,034,061 11.7% 25,481,221,804 USD
NOVARTIS INDIA LIMITED (500672) 17,450,680 70.7% 142,381,320 USD
ERASCA, INC. (ERAS) 12,307,692 8.94% 53,046,153 USD
PLIANT THERAPEUTICS, INC. (PLRX) 2,153,526 4.42% 41,627,658 USD
POSEIDA THERAPEUTICS, INC. (PSTX) 5,908,089 6.87% 31,312,872 USD
SOMALOGIC, INC. (SLGC) 10,422,469 5.56% 26,160,397 USD
MOLECULAR PARTNERS AG (MOLN) 1,739,130 4.82% 11,579,162 USD
GAMIDA CELL LTD. (GMDA) 4,336,759 5.83% 5,594,419 USD
TSCAN THERAPEUTICS, INC. (TCRX) 916,101 4.84% 1,419,957 USD
AYALA PHARMACEUTICALS INC 698,777 4.71% 279,511 USD
Markets and indexes
- Primary listing
- SMI / FTSE Eurotop 100, Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  NOVN.S
- Datastream Code :  
Company contact information
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Basel-Stadt

Phone : +41 61 324 11 11
Fax : +41 61 324 80 01
web site : http://www.novartis.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Novartis AG
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
NOVARTIS AG-1.09%192 980
JOHNSON & JOHNSON-4.04%441 560
ELI LILLY AND COMPANY-4.40%330 671
NOVO NORDISK A/S0.14%309 711
ROCHE HOLDING AG-0.52%277 411
MERCK & CO., INC.-3.68%270 958
ABBVIE INC.-8.79%260 586
PFIZER, INC.-12.04%248 389
ASTRAZENECA PLC-5.12%203 927
BRISTOL-MYERS SQUIBB COMPANY1.70%162 012
AMGEN INC.-2.32%135 999
SANOFI-0.13%121 451
GILEAD SCIENCES, INC.-2.60%104 880
GSK PLC-2.25%70 545
DAIICHI SANKYO CO., LTD.2.99%64 346
BAYER AG15.96%59 745
TAKEDA PHARMACEUTICAL COMPANY LIMITED1.58%49 785
CHUGAI PHARMACEUTICAL CO., LTD3.50%43 976
JIANGSU HENGRUI MEDICINE CO., LTD.13.00%40 941
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD10.16%28 265
ASTELLAS PHARMA INC.-1.57%27 605